» Articles » PMID: 10472525

Worsening of Left Ventricular Diastolic Function During Long-term Correction of Anemia with Erythropoietin in Chronic Hemodialysis Patients--an Assessment by Radionuclide Ventriculography at Rest and Exercise

Overview
Date 1999 Sep 3
PMID 10472525
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

We studied the effect of correction of anemia with erythropoietin on left ventricular systolic and diastolic function at rest and exercise in 17 chronic hemodialysis patients by means of maximum exercise testing and equilibrium gated radionuclide angiocardiography on three occasions: 1) initial--before erythropoietin administration, 2) intermediate--at the time when the target hemoglobin level reached 100 g/l, and 3) long-term--after 12 months of therapy. After correction of anemia, the patients showed a significant improvement in their response to exercise regarding maximal work load achieved, exercise duration and recovery time. Ejection fraction and peak ejection rate remained unchanged during therapy. At rest, peak filling rate was reduced from 2.62 +/- 1.0 (baseline) to 2.28 +/- 0.9 (intermediate) end-diastolic volume per second, p < 0.01, while no significant difference was observed during exercise. The time to peak filling rate was prolonged significantly during EPO therapy from 157 +/- 30 to 177 +/- 28 ms at rest, p < 0.05, and from 101 +/- 24 to 130 +/- 27 ms during exercise, p < 0.01. By the time of the late study, there were no significant differences between the late and intermediate study. In conclusion, amelioration of anemia with erythropoietin in hemodialysis patients produced improvement in exercise capacity, but diastolic function worsened with therapy and this effect was maintained during the long-term treatment, while systolic function at rest and exercise remained unchanged.

Citing Articles

Nonparallel Progression of Left Ventricular Structure and Function in Long-Term Peritoneal Dialysis Patients.

Shi Q, Zhu J, Feng S, Shen H, Chen J, Song K Cardiorenal Med. 2017; 7(3):198-206.

PMID: 28736560 PMC: 5511989. DOI: 10.1159/000466708.

References
1.
Goldsmith S, Dick C . Differentiating systolic from diastolic heart failure: pathophysiologic and therapeutic considerations. Am J Med. 1993; 95(6):645-55. DOI: 10.1016/0002-9343(93)90361-r. View

2.
Geskin G, Schulman D . Relation of changes in left ventricular peak filling rate during exercise to exercise performance in systemic hypertension and in healed myocardial infarction. Am J Cardiol. 1997; 80(9):1144-9. DOI: 10.1016/s0002-9149(97)00630-9. View

3.
Eschbach J, Abdulhadi M, Browne J, Delano B, Downing M, Egrie J . Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med. 1989; 111(12):992-1000. DOI: 10.7326/0003-4819-111-12-992. View

4.
Macdougall I, Lewis N, Saunders M, Cochlin D, Davies M, Hutton R . Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet. 1990; 335(8688):489-93. DOI: 10.1016/0140-6736(90)90733-l. View

5.
Juric M, Rupcic V, Topuzovic N, Jakic M, Brlosic R, Rusic A . Haemodynamic changes and exercise tolerance in dialysis patients treated with erythropoietin. Nephrol Dial Transplant. 1995; 10(8):1398-404. View